De-escalation protocols for dual antiplatelet therapies (DAPT) to manage acute coronary syndrome (ACS) during percutaneous coronary interventions (PCI) could enhance safety without compromising ischemic protection, the 4D-ACS trial concluded, after seeing a 49% reduction in adverse clinical events with shorter DAPT regimens.